| |
|
|
| |
Clopidogrel
/ Aspirin compo anti plated Therapy - No benefit; but
may harm those high-risk patients with Diabetes and
other CVD risks. |
|
| |
|
|
| |
May 2006
DOC News (Published by American Diabetes Association)
|
|
| |
|
|
| |
"The addition
of Clopidogrel (Plavix, Sanofi-Aventis/Bristol-Myers
Squibb) to a daily low-dose aspirin regimen does not
significantly reduce the incidence of death, heart attack,
or stoke among people with diabetes or other cardiovascular
risk factors, according to research presented at the
American College of cardiology (ACC) Scientific Session,
held March 11-14 in Atlanta." |
|
| |
|
|
| |
"While the
combination benefits people with a history of cardiovascular
disease (CVD), Clopidogrel appears to be linked to more
harmful side effects in people who have only CVD risk
factors, say investigators in the Clopidogrel for High
Athero-thrombotic Risk and Ischemia Stabilization, Management
and Avoidance (CHARISMA) study." |
|
| |
|
|
| |
"Combination
Therapy may be useful in a large, new group of patients-those
with established cardiovascular disease-but offers no
benefit whatsoever in patients only having risk factors
for developing vascular disease, "says lead investigator
Deepak L. Bhatt, MD, director of cardiovascular clinical
trials at the Cleveland Clinic on Ohio." |
|
| |
|
|
| |
"Yet the
addition of clopidogrel appears to increase the risk
of cardiovascular events for people with risk factors
but not established disease. Of the 3,284 patients with
multiple cardiovascular risk factors, 6.6% of those
who took aspirin plus Clopidogrel died or had a heart
attack or stoke, compared with 5.5% of those who received
aspirin plus placebo. Cardiac-related mortality nearly
doubled among those taking clopidogrel compared with
those on aspirin alone-2.2% of those on placebo died,
compared with 3.9% of those in clopidogrel." |
|
| |
|
|
| |
THE CHARISMA
TRIAL "ARGUES AGAINST THE USE OF DUAL ANTI-PLATELET
THERAPY" IN PATIENTS WITH MULTIPLE RISK FACTORS. |
|
| |
|
|
| |
"Results from
CHARISMA were published March 12 in the online edition
of the New England Journal of Medicine as they were
being presented at ACC." |
|
| |
|
|
| |
"The American
Heart Association on March 15 issued a statement saying
that the CHARISMA trial failed to support the use of
clopidogrel in patients with stable cardiovascular disease
or as a preventive measure in those at high risk for
CVD." |
|
| |
|
|
| |
For full details
log on to www.diabetes.org/docnews |
|
| |
|
|